Objective: An increasing body of evidence supports a major role for the insulin-like growth factors (IGFs) in the control of human fetal growth. Individual data at various times of pregnancy suggest that IGF-I and IGF-II levels remain stable up to the 33rd week of pregnancy. Thereafter, both increase to reach values 2–3 times higher at term. In order to provide an accurate reflection of fetal IGFs in utero, we sampled fetal blood from the umbilical cord by cordocentesis. Methods: We measured IGF-I and IGF-II in 12 fetuses longitudinally for up to 5 times between the 21st week of gestation and delivery. Results: All patients showed a progressive increase in IGF-I and IGF-II levels. Data determined during different time intervals (before 29th, 29th to 32nd, after 32nd week) were compared and the main increase was found after the 32nd week. The median for IGF-I before the 29th week was 33.5 ng/ml (range 19–40.5) and increased to 41 ng/ml (32–59) between the 29th to 32nd and further to 54.1 ng/ml (range 17–70) thereafter. During the same time interval, the median for IGF-II increased from 217 ng/ml (86–326) to 349 ng/ml (227–467). In 7 patients, cord blood after delivery was available. For IGF-II a further increase was consistently found after birth (from 282 ng/ml (175–511) to 393 ng/ml (297–513)), whereas only 2 fetuses showed an increase in IGF-I. Conclusion: We conclude that in human fetuses, IGF-I and IGF-II levels increase longitudinally throughout pregnancy. Therefore, they may become important markers of healthy fetal development.

1.
Gluckman PD, Harding JE: The physiology and pathophysiology of intrauterine growth retardation. Horm Res 1997;48(suppl 1):11–16.
2.
Leger J, Oury JF, Noel M et al: Growth factors and intrauterine growth retardation. I. Serum growth hormone, insulin-like growth factor (IGF)-I, IGF-II, and IGF-binding protein 3 levels in normally grown and growth-retarded human fetuses during the second half of gestation. Pediatr Res 1996;40:94–100.
3.
Bennett A, Wilson DM, Liu F et al: Levels of insulin-like growth factors I and II in human cord blood. J Clin Endocrinol Metab 1983;57:609–612.
4.
Giudice LC, de Zegher F, Gargosky SE, Dsupin BA, de las Fuentes L, Crystal RA, Hintz RL, Rosenfeld RG: Insulin-like growth factors and their binding proteins in the term and preterm human fetus and neonate with normal and extremes of intrauterine growth. J Clin Endocrinol Metab 1995;80:1548–1555.
5.
Lassarre C, Hardouin S, Daffos F, Forestier F, Frankenne F, Binoux M: Serum insulin-like growth factors and insulin-like growth factor binding proteins in the human fetus. Relationship with growth in normal subjects and in subjects with intrauterine growth retardation. Pediatr Res 1991;29:219–225.
6.
Reece EA, Wiznitzer A, Le E, Homko CJ, Behrman H, Spencer EM: The relation between human fetal growth and fetal blood levels of insulin-like growth factors I and II, their binding proteins, and receptors. Obstet Gynecol 1994;84:88–95.
7.
Wiznitzer A, Reece EA, Homko C, Furman B, Mazor M, Levy J: Insulin-like growth factors, their binding proteins, and fetal macrosomia in offspring of nondiabetic pregnant women. Am J Perinatol 1998;15:23–28.
8.
Langford K, Nicolaides K, Miell JP: Maternal and fetal insulin-like growth factors and their binding proteins in the second and third trimester of human pregnancies. Hum Reprod 1998;13:1389–1393.
9.
Hadlock FP, Harrist RB, Sharman RS, Deter RL, Park SK: Estimation of fetal weight with the use of head, body and femur measurements – A prospective study. Am J Obstet Gynecol 1995;151:333–337.
10.
Lubchenco LO, Hansman C, Dressler M, Boyd E: Intrauterine growth as estimated from liveborn birth-weight data at 24–42 weeks of gestation. Pediatrics 1966;37:403.
11.
Nicolaides KH, Soothill PW, Rodeck CH, Campbell S: Ultrasound-guided sampling of the umbilical cord and placental blood to assess fetal well-being. Lancet 1986;i:1065–1067.
12.
Blum WF, Breier BH: Radioimmunoassays for IGFs and IGFBPs. Growth Regul 1994;4(suppl 1):11–19.
13.
Halvorsen S, Bechensteen AG: Physiology of erythropoietin during mammalian development. Acta Paediatr Suppl 2002;91:17–26.
14.
Kao PC, Matheny AP, Lang CA: Insulin-like growth factor I comparisons in healthy twin children. J Clin Endocrinol Metab 1988;78:310–312.
15.
Verhaeghe J, Loos R, Vlietnick R, Van Herck E, van Bree R, De Schutter AM: C-peptide, insulin-like growth factors I and II, and insulin-like growth factor binding protein-1 in cord serum of twins: Genetic versus environment regulation. Am J Obstet Gynecol 1996;175:1180–1188.
16.
Unterman T, Lascon R, Gotway MB, Oehler D, Gounis A, Simmons RA, Ogata ES: Circulating levels of insulin-like growth factor binding protein-1 (IGFBP-3) and hepatic mRNA are increased in the small for gestational age fetal rat. Endocrinology 1990;127:2035–2037.
17.
Straus DS, Ooi GT, Orlowski CC, Recher MM: Expression of the genes for insulin-like growth factor (IGF)-I, IGF-II and IGF-binding proteins-1 and -2 in fetal rat under conditions of intrauterine growth retardation caused by maternal fasting. Endocrinology 1991;128:518–525.
18.
Shambaugh GE 3rd, Radosevich JA, Glick RP, Gu DS, Metzger BE, Unterman TG: Insulin-like growth factors and binding proteins in the fetal rat: Alterations during maternal starvation and effects in fetal brain cell culture. Neurochem Res 1993;18:695–703.
19.
Bassett NS, Oliver MH, Breier BH, Gluckman PD: The effect of maternal starvation on plasma insulin-like growth factor I concentration in the late gestation ovine fetus. Pediatr Res 1990;27:401–404.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.